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Abstract
Background: Hearing loss is a frequent long-term complication of pneumococcal meningitis (PM). Its main
pathological correlate is damage to the organ of Corti and loss of spiral ganglion neurons. The only current
treatment option is cochlear implants which require surviving neurons. Here, we investigated the impact of
systemically applied neurotrophin-3 (NT-3) on long-term hearing loss and the survival of neurons.
Methods: Eighteen hours after infection with S. pneumoniae, C57BL/6 mice were treated with a combination of
ceftriaxone with NT-3 or dexamethasone or placebo. Hearing, cochlear damage, and brain damage were assessed
by audiometry and histology.
Results: The main findings from immunohistochemical visualization of neurotrophins (NT-3, BDNF) and their
receptors (TrkB, TrkC, and p75) in the cochlea were (i) enhanced staining for the cell survival-promoting receptor
TrkB and (ii) increased NT-3 staining in NT-3 treated mice, showing that systemically applied NT-3 reaches the
cochlea. The major effects of adjunctive NT-3 treatment were (i) a reduction of meningitis-induced hearing
impairment and (ii) a reduction of spiral ganglion neuronal loss. The efficacy of NT-3 therapy was comparable to
that of dexamethasone.
Conclusion: Systemically applied NT-3 might be an interesting candidate to improve hearing outcome after
pneumococcal meningitis.
Introduction
Despite calculated antibacterial therapy and supportive
intensive care, bacterial meningitis remains a very ser-
ious infectious disease with approximately 1.2 million
cases per year worldwide causing 135.000 deaths [1].
The most frequent causative pathogen in adults is Strep-
tococcus (S.) pneumoniae, leading to death in 15-25% of
cases [2]. Up to 50% of survivors suffer from long-term
sequelae. Sensorineural hearing loss is one of the most
prevalent acute and long-term complications. It can
manifest as uni- or bilateral, and as mild to severe hear-
ing impairment, affecting one fourth of survivors [2-4].
In the course of acute bacterial meningitis, infection
spreads most likely from the subarachnoid space
through the cochlear aqueduct, reaching the perilym-
phatic spaces and causing suppurative labyrinthitis [5-7].
A massive immune response directed against the
bacteria leads to collateral damage of the cochlea’so w n
tissue [8,9]. Histopathological findings show a blood-
labyrinth barrier disruption, damage to the organ of
Corti, and destruction of spiral ganglion cells in the
acute phase [2,10-14]. Loss of spiral ganglion neuronal
cells as well as fibrocytic reorganisation of the perilym-
phatic spaces, leading to labyrinthitis ossificans, are
noted as long-term residues [5,15]. In addition to the
inflammatory response, direct bacterial toxicity may be a
factor driving cochlear damage in meningitis. E.g., intra-
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cochlear injury [16].
Currently, the only treatment option for severe long
term hearing loss in pneumococcal meningitis is surgical
implantation of a cochlear implant [17,18]. The efficacy
of cochlear implant surgery depends on multiple factors,
which include cognitive measures, proper surgical inser-
tion, and the length of time after onset of deafness
[19-21]. Moreover, at least a critical number of neurons
seem necessary for proper functioning of a cochlear
implant. This is underscored by the finding of a recent
study that all patients who benefited from cochlear
implantation had at least some spiral ganglion neuronal
cells (SGCs) remaining (whereas peripheral nerve fibres
or hair cells were completely absent in most patients)
[22]. Bacterial meningitis can result in a dramatic reduc-
tion in the number of SGCs [6]. Additionally, the GC
population was found to decline (further) over time
after meningitis [23,24]. Therefore, therapeutic
approaches to protect neurons from cell death during
and after meningitis might have the potential to improve
the efficacy of cochlear implants.
The neurotrophins are a group of proteins that induce
survival, differentiation and neurite outgrowth. Two
such neuroprotective agents, neurotrophin-3 (NT-3) and
brain-derived neurotrophic factor (BDNF), play a signifi-
cant role in the cochlea [25]. They are released by
cochlear sensory cells and act via tyrosine kinase recep-
tors (TrkB and TrkC) and p75-receptors that are
expressed by spiral ganglion neuronal cells [26,27]. Stu-
dies using knock-out mice lacking either BDNF, NT-3,
or both neurotrophins have demonstrated that both
neurotrophic agents play a crucial role in the develop-
ment and maintenance of spiral ganglion neuronal cells
[28,29]. Administration of neurotrophin via mini-
osmotic pumps, drug-eluting cochlear implants or viral
vectors in animal studies have shown promising results
in protecting auditory neurons and even in partly coun-
teracting hearing loss [17,30-33]. In this study, we inves-
tigated the impact of systemically administered NT-3 on
the preservation of cochlear neurons and hearing loss.
Furthermore, we investigated the impact of NT-3 on
neurologic outcome in a mouse model of experimental
pneumococcal meningitis. Adjunctive therapy with
NT-3 was compared to adjunctive dexamethasone treat-
ment which has been recommended for adjunctive treat-
ment of pneumococcal meningitis in adults [34,35].
Methods
Mouse model of pneumococcal meningitis
A well-characterized mouse model of pneumococcal
meningitis was used in this study [36]. The model has
been developed in C57BL/6 mice which are widely used
for studies of cerebral infection and for studies on
acquired hearing loss. C57BL/6 mice, however, carry the
AHL locus for genetic hearing loss (Cdh23
ahl) [37]. All
animals were of the same age (4-6 weeks), at a time
point months before age-related hearing loss occurs in
these mice [38]. In brief, meningitis was induced by
transcutaneous intracisternal injection of 15 μl of a bac-
terial suspension containing 10
6 colony forming units
(cfu)/ml of S. pneumoniae (SP) D39 or placebo under
short-term anaesthesia with enflurane. Mice were
w e i g h e d ,p u ti n t oc a g e s ,a l l o w e dt ow a k eu pa n df e d
with a standard diet and water ad libitum. Eighteen
hours after infection, when all mice showed clinical
signs of meningitis, intraperitoneal therapy with ceftriax-
one was begun and continued for a total of 4 days.
Furthermore, animals received adjunctive therapy or pla-
cebo (see experimental groups). Two weeks after infec-
tion, mice were deeply anaesthetized with ketamine and
xylazine (SIGMA, St. Louis, MO, USA) and perfused
transcardially with 15 ml of ice-cold phosphate buffered
saline (PBS) containing 10 U/ml heparin. Temporal
bones and brains were dissected, fixed in 4% formalin,
decalcified in PBS containing 10% EDTA (SIGMA, St.
Louis, MO, USA), and embedded in paraffin. All animal
experiments were approved by the government of Upper
Bavaria, Germany.
Experimental groups in the mouse model
The following groups were investigated: (i) mice intracis-
ternally injected with 15 μl sterile phosphate-buffered sal-
ine (PBS) (CON; n = 8); (ii) mice intracisternally injected
with SP, treated with 100 mg/kg ceftriaxone (Roche,
Grenzach-Wyhlen, Germany) daily for 4 days and 0.5 ml
isotonic saline every 2nd day for 2 weeks (PLC, n = 16);
(iii) mice intracisternally injected with SP, treated with
100 mg/kg ceftriaxone daily for 4 days and 0.5 mg/kg
dexamethasone (Merck, Darmstadt, Germany) every 8 h
for a total of 4 days (DEX, n = 12); (iv) mice intracister-
nally injected with SP, treated with 100 mg/kg ceftriax-
one daily for 4 days and 25 μg/kg Neurotrophin-3 (R&D
Systems, Wiesbaden, Germany) every 2nd day for
2 weeks (NT-3, n = 11). Infected placebo-treated mice
(PLC) were compared with uninfected mice (CON),
showing successful infection and development of menin-
gitis and meningitis-associated hearing loss. To detect a
possible adjunctive treatment effect, animals who
received adjunctive therapy with dexamethasone (DEX)
or neurotrophin-3 (NT-3) were compared with placebo-
treated mice (PLC) and with each other.
Clinical assessment of mice
Animals were investigated clinically before infection,
18 h, 42 h, and 2 weeks after infection. Clinical scores
(CS) were determined as previously described reaching 0
points if there were no clinically noticeable signs of
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the following criteria were assessed: (i) beam balancing,
(ii) postural reflexes, (iii) piloerection, (iv) epileptic sei-
zures, and (v) level of consciousness. For determination
of explorative activity, each mouse was put in the mid-
dle of a 42 × 42 cm box divided into 9 squares and
allowed to explore the box for two minutes. The num-
ber of squares which the mouse passed through within
the two minutes time interval was counted.
Determination of hearing
Hearing was determined by auditory brain-stem
responses (ABRs) at the end of the experiment. Mice
were anaesthetized intraperitoneally with 100 mg/kg
ketamine and 5 mg/kg xylazine. Needle electrodes were
placed over each mastoid (negative pole), the vertex
(positive pole), and the neck (reference). Impedances
were controlled to be below 5 kΩ. Square-wave click
impulses (duration: 100 ms; frequency: 20Hz) and tone
bursts of 1 and 10 kHz (duration: 4 ms; frequency:
23.4 Hz) were delivered by earphones (E-A-RTONE3A,
A e a r oC o m p a n y ,I n d i a n a p o l i s ,I N ,U S A ) .A B R sw e r e
amplified (x250.000), band-pass filtered (150-10,000Hz),
and averaged (n = 1000) using a Neuroscreen Plus (Jae-
ger-Toennies, Freiburg, Germany). To determine the
hearing threshold, we started with an impulse of 105 dB
Sound Pressure Level (SPL) and reduced the intensity in
5 dB SPL steps. The lowest stimulus intensity that eli-
cited visual ABRs was considered to be the hearing
threshold. If a response could not be elicited at 105 dB
SPL, stimulus intensities of up to 130 dB SPL were
tested.
Histologic assessment of cochleae
For histological analysis, midmodiolar sections (thick-
ness 7 μm) of mouse temporal bone were deparaffinized,
rehydrated, and stained with Mayer’s haematoxylin and
eosin (H&E; MERCK, Darmstadt, Germany). Sections
were digitized using an Olympus BX51 microscope
(Olympus Optical, Hamburg, Germany), connected to a
camera (Moticam 5000, Motic Deutschland GmbH,
Wetzlar, Germany). Two sections of each cochlea were
analyzed and the mean was calculated for statistics.
For determination of the spiral ganglion neuronal den-
sity in the cochlea, the area of each spiral ganglion was
measured (Image Tool Version 3.00, University of Texas
Health Science Center, San Antonio, TX, USA) and
morphologically intact spiral ganglion neurons (criteria:
round cell body containing a nucleus and homogenous
cytoplasm) were counted within this area.
A regular cochlear finding 2 weeks after pneumococ-
cal meningitis is fibrocytic occlusion of the scala tym-
pani, indicating early labyrinthitis ossificans. The degree
of occlusion was evaluated by measurement of the
occluded area of the basal turn of the tympanic scala
(Image Tool Version 3.00, University of Texas Health
Science Center, San Antonio, TX, USA). The occluded
area was expressed as a percentage to the total area of
the basal scala tympani.
The integrity of the organ of Corti was evaluated as (i)
existing and intact, or (ii) absent or respectively
damaged. The integrity of the organ of Corti was
defined as intact inner and outer hair cells as well as an
intact architecture of supporting cells.
Immunohistochemical detection of neurotrophins and
neurotrophin receptors
Cochleae were stained for NT-3 and BDNF as well as
their receptors TrkB, TrkC (both inducing neuroprotec-
tive effects on neurons) and p75 (inducing apoptosis in
neurons) using immunohistochemistry. Sections were
deparaffinized and placed in a microwave for boiling in
10 mM citrate buffer (pH 6) for antigen retrieval. Endo-
genous peroxidases were blocked by incubation with
0.3% hydrogen peroxide in methanol (MERCK, Hohen-
brunn, Germany). Sections were incubated with one of
the following primary antibodies: (i) rabbit polyclonal
anti-NT3 (1:500 in blocking solution, Alomone Labs
Ltd, Jerusalem, Israel); (ii) rabbit polyclonal anti-BDNF
(1:500 in blocking solution, Alomone Labs Ltd, Jerusa-
lem, Israel); (iii) rabbit polyclonal anti-TrkB (1:500 in
blocking solution, Novus Biologicals Inc., Littleton, CO,
USA); (iv) goat monoclonal anti-mouse TrkC (1:200 in
blocking solution, R&D Systems, Wiesbaden, Germany);
(v) rabbit polyclonal anti-human p75 NTR (1:200 in
blocking solution, Alomone Labs Ltd, Jerusalem, Israel)
or (vi) blocking solution without primary antibody
(negative control) in a humidified chamber overnight.
Then, sections were incubated with secondary antibo-
dies (biotinylated anti-rabbit IgG made in goat or
anti-goat IgG made in horse according to the primary
antibody used; both 1:200, Vector Labs, Burlingame,
CA, USA). Binding of the secondary antibody was visua-
lized with streptavidin horse-radish peroxidase (DAKO,
Hamburg, Germany) and diaminobenzidine (Vector
Labs, Burlingame, CA, USA), which yields a brown reac-
tion product. Between all reaction steps, slides were
rinsed with 0.1 M PBS (pH 7.4). Counterstaining was
performed using Mayer’s hematoxylin.
For assessment of immunohistochemical staining pat-
terns, the most basal spiral ganglion was digitized. Pic-
tures were blinded and printed on 20 × 30 cm color
prints. Then, four reviewers (one professor of neuro-
pathology, one assistant professor of neurology, and two
residents of neurology with experience in neuropathol-
ogy) independently grouped the printouts according to
(i) homogeneity of the neuronal staining, (ii) intensity of
the neuronal staining, and (iii) intensity of extracellular
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cessfully if >80% of blinded slides were grouped together
correctly.
Histologic assessment in the brain
For histological analysis, 7-μm-thick hippocampal sec-
tions of mouse brains were used. For assessment of gen-
eral brain pathology, sections were stained with Mayer’s
haematoxylin and eosin (H&E), Prussian blue (MERCK,
Darmstadt, Germany) (detection of iron as a marker for
residues of parenchymal hemorrhages), glial fibrillary
acidic protein (GFAP, detection of astrocyte activation
(rabbit GFAP polyclonal, 1:3000, DAKO, Hamburg,
Germany), and neurofilament and amyloid precursor
protein (APP, detection of axonal injury, Neurofilament
m o n o c l o n a l ,1 : 5 0 0 ,D A K O ;APP A4 monoclonal, 1:100,
Chemicon, Billerica, MA, USA; secondary antibody:
swine anti-rabbit biotinylated, concentration 1:150,
DAKO, Hamburg, Germany, visualization with streptavi-
din-horse radish peroxidase and diaminobenzidine). Acti-
vated (GFAP-positive) astrocytes (appearing with a round
nucleus and more than two GFAP-positive processes)
were counted within predetermined areas (cortex and
hippocampus).
Statistical analysis
All experimental procedures were performed in a
blinded fashion. Data were analyzed with SYSTAT 9
(SPSS, Chicago, IL, USA) using a t-test for independent
variables. P < 0.05 was considered significant. A Bonfer-
roni correction was used to address the problem of mul-
tiple comparisons. Correlation analyses were performed
according to Spearman. Data are displayed as mean ±
standard deviation (SD).
Results
Clinical characteristics of meningitis
At 18 hours after infection, when treatment was begun,
all infected mice had developed clinical signs of disease
such as weight loss, an increased clinical score and
reduced explorative activity. Within the next 24 hours
following the start of the antibiotic therapy, the infected
mice improved. By two weeks after infection, the clinical
score of PLC mice almost completely resolved despite
slight motor deficits and a reduced explorative activity
(Figure 1). Mortality rates were similar in all groups
(mortality PLC 4/16, NT-3 3/11, DEX 2/12); motor defi-
cits and explorative activity did not differ between PLC,
DEX, and NT-3.
Uninfected control animals (CON) that received intra-
cisternal sterile PBS also showed a slight decrease of
explorative activity, possibly due to a combination of a
mild traumatic effect and/or habituation. However, their
clinical scores were not altered, and they did not show
signs of infection (such as pilo-erection), meningeal irri-
tation or neurologic deficits.
Impact of adjunctive NT3 and dexamethasone on hearing
thresholds (HT)
Two weeks after infection, infected placebo-treated mice
showed a significant elevation of hearing thresholds. An
elevation of hearing thresholds was especially noted for
high frequency hearing (10 kHz). This reflects the circum-
stance that cochlear damage was worst in the basal turn.
Adjuvant therapy with NT-3 as well as dexamethasone
mildly improved hearing outcome at two weeks after
infection. (Figure 2)
Impact of NT-3 and dexamethasone on cochlear spiral
ganglion neuronal densities and cochlear occlusion
Meningitis led to damage of the organ of Corti, fibrocy-
t i co c c l u s i o no ft h es c a l at y m p a n i ,a n dl o s so fn e u r o n s
in the basal spiral ganglion two weeks after infection
(CON vs. PLC, Figure 3). The morphology of the organ
of Corti was severely damaged or completely absent two
weeks after infection with bacterial meningitis (CON vs.
PLC: 0% vs. 54% (percentage of destroyed or completely
absent organs vs. total number of investigated organs of
Corti)). Adjuvant treatment, neither with NT-3 nor with
dexamethasone, resulted in preservation of the organ of
Corti (NT-3 29%, DEX 54% (destroyed or completely
absent/total number of investigated organs of Corti)).
There was a significant decline of neuronal density in
the basal spiral ganglion of infected mice (PLC) com-
pared to uninfected controls (70%). Neuronal densities
in the basal spiral ganglion correlated inversely with
high frequency hearing thresholds (r
2 = 0.51). Adjuvant
therapy with NT-3 and dexamethasone led to a reduced
loss of intact neurons in the spiral ganglion in compari-
son with the placebo group (Figure 4A).
Within infected mice, it was mainly the basal scala
tympani that was obliterated with loose connective tis-
sue. The mean occluded area in infected and placebo-
treated animals (PLC) was 75.1% ± 27.52%. In contrast,
the scala media (endolymphatic space) and the scala ves-
tibuli did not show occlusions on a regular basis. There
was no significant difference in regard to occlusion
among the infected groups (Figure 4B). In summary, our
data suggest that the hearing protective effects of both
NT-3 and dexamethasone are mediated by a reduced
loss of spiral ganglion neuronal cells.
Neurotrophins and their receptors in the spiral ganglion
Two weeks after infection, there was a reduced number
of intact neurons in the basal spiral ganglion of infected
mice, which were more heterogeneously stained for neu-
rotrophin NT-3 and BDNF than those of healthy control
animals. All NT-3-treated mice showed an additional
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that was not detected in any other group, indicating that
systemically applied NT-3 reached the cochlea.
Whereas uninfected controls stained homogeneously
for TrkB, a more intense staining of most neurons was
found in infected animals. This finding could possibly
reflect an up-regulation of TrkB to increase the neuron’s
opportunity to survive a situation with decreased neuro-
trophin levels (Figure 5). The p75-positive neurons of
uninfected controls and infected mice showed no differ-
ence in staining pattern; in addition, staining patterns
f o rT r k Ca n dB D N Fw e r en o ta l t e r e db e t w e e nt h e
groups (not shown).
Morphological changes in the cortex and hippocampus
An elevated number of GFAP-positive astrocytes was
found in the cortex of infected mice (PLC), reflecting
activation of astrocytes as an indicator of former brain
Figure 1 Clinical Signs of Meningitis. All infected mice showed clinical signs of disease 18 h after injection, reflected in (A) an elevated clinical
score and (B) a tenfold reduced explorative activity compared to uninfected controls. Two weeks after infection, animals that had received
adjunctive dexamethasone treatment showed explorative activity similar to uninfected controls whereas explorative activity in animals that had
received placebo or adjunctive NT-3 was still reduced. (#) P < 0.05 as compared to uninfected controls, (*) p < 0.05 as compared to infected
animals receiving ceftriaxone and placebo.
Figure 2 Adjunctive dexamethason and NT-3 decrease hearing loss.M i c ew e r ea s s e s s e df o r( A )c l i c ks t i m u l i ,( B )l o wf r e q u e n c yh e a r i n g
(1 kHz stimuli), and (C) high frequency hearing (10 kHz stimuli). In infected animals, a significant increase of hearing thresholds was observed.
The elevation of hearing thresholds was most severe for high frequency hearing. Adjunctive treatment with dexamethasone or NT-3 improved
hearing significantly compared to mice treated with ceftriaxone plus placebo. There was no difference between dexamethasone and NT-3
treated animals. (#) P < 0.05 as compared to uninfected controls, (*) p < 0.05 as compared to infected animals receiving ceftriaxone and
placebo.
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with a patent scala tympani (+) and (C) a dense population of neurons in the spiral ganglion. In infected animals that were treated with
ceftriaxone and placebo, (D and E) dense fibrocytic occlusion of the scala tympani (+) was observed, (E) the organ of Corti (®) appeared
destroyed, and (F) neuronal densities were decreased. Adjunctive treatment with (G, H, and I) dexamethasone or (K, L, and M) NT-3 did not lead
to significant changes in (G, H, K, and L) fibrocytic cochlear occlusion or damage to hair cells but (I and M) both therapies rescued neuronal
ganglion cells from death, reflected in less neuronal loss. The morphology of the cochlea did not differ between animals treated with
dexamethasone or NT-3. Staining was performed with hematoxylin and eosin.
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2 vs.
88.9 ± 57.5 astrocytes/mm
2, p = 0.003). There were no
significant differences between the various treatment
groups (NT-3 55.5 ± 28.3 astrocytes/mm
2, DEX 116.3 ±
51.5 astrocytes/mm
2) (Figure 6). Signs of previous par-
enchymal bleeding were absent (negative staining for
iron). We also did not find pathological changes sugges-
tive of necrosis or axonal injury in hippocampal or cor-
tical areas two weeks after infection (data not shown).
Discussion
In this study, a mouse model of pneumococcal meningi-
tis was used that featured all typical clinical and histo-
morphological findings of meningitis-associated
labyrinthitis and hearing loss to study the impact of
adjunctive neurotrophins on cochlear damage. We
demonstrated that (i) intraperitoneally applied NT-3
reached the cochlea, (ii) adjunctive NT-3 treatment led
to a significant decrease of spiral ganglion neuronal
damage and hearing loss, (iii) the effect of NT-3 therapy
was comparable to the benefit of adjunctive therapy
with dexamethasone, and (iv) changes in brain pathol-
ogy could not be observed after treatment with NT-3.
Two weeks after infection we observed meningitis-
associated morphological changes in the cochlea, namely
fibrocytic occlusion of the scala tympani, damage to and
often loss of the organ of Corti, as well as a significant
decline of neurons in the spiral ganglion. The morpho-
logical alterations dominated in the basal turn of the
cochlea, where high frequency hearing is localized. This
was associated with pronounced high frequency hearing
impairment as measured with auditory brainstem
responses. These findings are similar to previous experi-
mental observations and data from humans with bacter-
ial meningitis, suggesting a spread of the infection from
the brain to the inner ear via the cochlear aqueduct that
enters the basal turn of the scala tympani [2,23].
Our immunohistochemical findings indicate that intra-
peritoneally applied NT-3 actually reached the area of
interest in the cochlea. A previously published study
described findings consistent with our study: After sys-
temic application of NT-3 (via a subcutaneous Alzet
micro-osmotic pump) neuroprotective effects were
noticed in the dorsal root ganglia [40]. This demonstrates
that NT-3 can pass the blood-labyrinth-barrier (in con-
trast to BDNF that has a larger molecular size), and this
led us to test the effect of NT-3 in our mouse model of
meningitis-associated hearing loss [41]. Another possible
circumstance that could have facilitated the passage of
NT-3 into the cochlea in our model is disruption of the
blood-labyrinth barrier that occurs during the course of
acute bacterial meningitis [5]. Importantly, systemic
application of NT-3 does not require specific equipment
as is the case for neurotrophins that are applied locally
Figure 4 Adjunctive dexamethasone and NT-3 decrease spiral ganglion neuronal loss. (A) The density of intact neurons in the spiral
ganglion of the cochlea was significantly reduced in PLC-treated animals two weeks after infection compared to uninfected control animals.
Treatment with dexamethasone as well as NT-3 counteracted this decline and led to a decreased loss of neurons. (B) The scala tympani of
cochleae of infected mice (PLC) were occluded with dense fibrocytic tissue which was not observed in healthy uninfected control animals
(CON). Adjunctive dexamethasone or NT-3 did not have an impact on cochlear occlusion. (#) P < 0.05 as compared to uninfected controls,
(*) p < 0.05 as compared to infected animals receiving ceftriaxone and placebo.
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homogeneously was higher in (A,E,I, and N) uninfected controls in contrast to infected mice ((B,F,K, and O) placebo-treated; (C,G,L, and P)
dexamethasone-treated; (D,H,M, and Q) NT-3-treated). Only (D,H) NT-3-treated mice showed increased staining for NT-3, indicating that
systemically applied NT-3 reached the spiral ganglion. (For staining details and qualitative blinded assessment of pictures see text).
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electrodes; and it does not bear the risk of local infection
[42].
Adjuvant NT-3 led to a reduced loss of neurons in the
spiral ganglion and lowered hearing loss after meningi-
tis. A reduction of spiral ganglion neuronal loss through
adjunctive NT-3 has not been previously shown in bac-
terial meningitis-associated labyrinthitis. Our data is
strengthened by a recent study that demonstrated that
NT-3 can preserve cochlear spiral ganglion neurons
after ototoxic hair cell damage when locally applied [18].
Hair cell damage is a predominant correlate of long-
term meningitis-associated hearing loss and was also
present in our model. Possibly this contributes to the
loss of neurons in the ganglion after meningitis through
reduced depolarization of cells followed by neuronal
inactivity and neuronal death [12,43]. Furthermore, a
decline of hair cells could lead to a reduced supply of
BDNF and NT-3, necessary for neuronal survival [44].
This might explain the neuroprotective effect of exogen-
ous NT-3 administration after meningitis. Protection of
neurons in the spiral ganglion after meningitis is impor-
tant, since a critical number of surviving neurons are a
prerequisite for the functioning of cochlear implants,
which currently represents the only available treatment
option for sensorineural hearing loss. Furthermore,
NT-3 not only reduced neuronal degeneration but even
led to a reduction of hearing loss. Therefore, systemic
adjuvant therapy with NT-3 might be an option for
co-treatment of patients with pneumococcal meningitis.
Systemic administration of neurotrophins can lead to
side effects. However the complete range of side effects
cannot be predicted at present, because of a lack of
experience and a lack of knowledge of the role of neuro-
trophins in certain systemic diseases: Neurotrophins
have been shown to be present constitutively in the
blood, and to be elevated in certain pathologic condi-
tions. E.g., high levels of neurotrophins have been
Figure 6 Astrocyte activation after meningitis. GFAP-positive astrocytes were not seen (A) in brains of uninfected control mice. In contrast,
(B-D) in brains of infected mice, a high density of GFAP-positive astrocytes in the cortex reaching far into the superficial layer was observed. (B)
Compared to infected placebo-treated animals, this was not altered by adjunctive treatment with (C) dexamethasone or (D) NT-3. GFAP staining
(brown).
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lupus erythaematosis, allergic disease, or asthma as well
as type 1 diabetes and metabolic syndrome [45-48].
In vitro, an elevation of neurotrophins in response to
proinflammatory cytokines has been found, suggesting a
possible link between neurotrophins and inflammatory
processes [49]. So far, it is suspected that systemic
administration of TrkB agonists can lead to anorexia and
weight loss, and systemic therapy with nerve growth fac-
tor (NGF) has been shown to evoke myalgias and arthral-
gias [50,51]. To date, systemic neurotrophin-3 has only
been applied to humans in small case series with limited
side effects [52]. Due to this limited experience and the
fact that clinical studies on adjunctive NT-3 after menin-
gitis are lacking, systemic NT-3 cannot be recommended
for the use in humans with meningitis at this time.
With respect to changes in the brain, a benefit of
adjunctive therapy with NT-3 or dexamethasone could
not be observed: activation of astrocytes, for instance,
reflected in GFAP-positive astrocytes, was not altered by
adjunctive therapy. Gliosis occurs in response to all
forms of CNS injury or disease. The functions of reac-
tive astrocytes are not well understood and both harm-
ful and beneficial activities have been attributed to these
cells. However, we could not detect severe brain damage
two weeks after infection in our model. Signs of par-
enchymal bleeding or axonal injury, which are typical
findings of severe experimental murine meningitis, have
not been observed as documented by negative iron
staining of the brain [53,54]. The most likely explanation
is the early start of antibiotic therapy at 18 hours after
infection. This time frame was chosen because the focus
of the study was on a possible treatment effect on hear-
ing loss, requiring less-than-complete damage of the
inner ear as observed when treatment is begun early
(18 h after infection). A later start of antibiotic therapy
in mice (e.g. 24 h after infection) results in an irreversi-
ble hearing impairment [55]. In addition, brain pathol-
ogy is then more pronounced (e.g. damage of neurons,
vasculitis, and ischemia) and mortality is higher [53,54].
Therefore, a possible effect of adjunctive therapy on
pathological changes in the brain might have been
missed in the current study.
The impact of long-term NT-3 therapy on long-term
hearing loss was compared not only with placebo-trea-
ted animals but also with animals that received adjunc-
tive therapy with dexamethasone, which has been
recommended as the standard adjunctive therapy of
choice in patients with pneumococcal meningitis
[34,56]. Here, therapy with NT-3 was of clear benefit in
comparison with adjunctive placebo and similar in effec-
tiveness to adjunctive dexamethasone. Just recently,
however, the benefit of dexamethasone in pneumococcal
meningitis has been questioned by a large meta-analysis
of individual patient data [57]. Currently, it is unclear
how this observation will affect future treatment guide-
lines. This highlights the need for further adjunctive
therapeutic approaches. At present, dexamethasone is
not recommended in patients with immunosuppression
and contraindications to corticosteroids. In such
patients, adjunctive NT-3 therapy might be an interest-
ing alternative to dexamethasone. At present, data on
NT-3 therapy in pneumococcal meningitis is still experi-
m e n t a la n de x p e r i e n c eo np o s s i b l es i d ee f f e c t so fs y s -
temic NT-3 treatment as well as the high costs of NT-3
need to be kept in mind.
In conclusion, systemically applied NT-3 reached the
spiral ganglion, leading to a reduced loss of spiral ganglion
neurons. Furthermore, this neuroprotective agent had a
positive impact on hearing thresholds. Compared with the
currently established adjuvant therapy with dexametha-
sone, NT-3 showed similar effects. Systemic NT-3 could
be a valid alternative to reduce damage to spiral ganglion
neuronal cells and hearing loss after bacterial meningitis.
List of abbreviations
ABR: auditory brain-stem responses; AHL: age-related hearing loss;
APP: amyloid precursor protein; BDNF: brain derived neurotrophic factor;
cfu: colony forming units; Con: controls; CS: clinical score;
Dex: dexamethasone; EDTA: ethylenediaminetetraacetic acid; GC: ganglion
cell; GFAP: glial fibrillary acidic protein; H&E: haematoxylin and eosin;
HT: hearing threshold; IgG: Immunoglobulin G; NT-3: Neurotrophin-3;
PBS: phosphate buffered saline; Plc: placebo; PM: pneumococcal meningitis;
SD: standard deviation; SGC: spiral ganglion cell; SP: Streptococcus
pneumonia; SPL: sound pressure level; TrkB: tyrosine kinase receptor B;
TrkC: tyrosine kinase receptor C.
Acknowledgements
We thank Prof. Dr. Sven Hammerschmidt (University of Greifswald,
Greifswald, Germany) for providing the pneumococci. The project was
financed by the Meningitis Research Foundation (MRF), which is highly
appreciated. Also, we are grateful for the financial aid of the Deutsche
Forschungsgemeinschaft (DFG), the University of Munich (FöFoLe), the
Friedrich Baur Stiftung, and the Else Kroener Fresenius Foundation (EKFS).
Author details
1Department of Neurology, Klinikum Grosshadern, Ludwig Maximilians
University Munich, Marchioninistrasse 15, 81377 Munich, Germany.
2Center of
Neuropathology and Prion Research, Ludwig Maximilans University Munich,
Feodor-Lynen-Strasse 23, 81377 Munich, Germany.
Authors’ contributions
The work presented here was carried out in collaboration between all
authors. Experimental procedures were carried out by MK and CD with
technical assistance of BA. Histological assessment of slides was performed
by CD, MK, UK, AG, and TH. The manuscript was drafted by CD and MK and
discussed and edited by all co-authors. All authors have read and approved
the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 16 August 2010 Accepted: 24 January 2011
Published: 24 January 2011
References
1. Koedel U: Toll-like receptors in bacterial meningitis. Curr Top Microbiol
Immunol 2009, 336:15-40.
Demel et al. Journal of Neuroinflammation 2011, 8:7
http://www.jneuroinflammation.com/content/8/1/7
Page 10 of 122. Klein M, Koedel U, Kastenbauer S, Pfister HW: Nitrogen and oxygen
molecules in meningitis-associated labyrinthitis and hearing impairment.
Infection 2008, 36:2-14.
3. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moisi JC, Were F, Levine OS:
Sequelae due to bacterial meningitis among African children: a
systematic literature review. BMC Med 2009, 7:47.
4. Klein M, Schmidt C, Kastenbauer S, Paul R, Kirschning CJ, Wagner H, Popp B,
Pfister HW, Koedel U: MyD88-dependent immune response contributes to
hearing loss in experimental pneumococcal meningitis. J Infect Dis 2007,
195:1189-1193.
5. Klein M, Koedel U, Pfister HW, Kastenbauer S: Morphological correlates of
acute and permanent hearing loss during experimental pneumococcal
meningitis. Brain Pathol 2003, 13:123-132.
6. Merchant SN, Gopen Q: A human temporal bone study of acute bacterial
meningogenic labyrinthitis. Am J Otol 1996, 17:375-385.
7. Klein M, Koedel U, Pfister HW: Oxidative stress in pneumococcal
meningitis: a future target for adjunctive therapy? Prog Neurobiol 2006,
80:269-280.
8. Weber JR, Tuomanen EI: Cellular damage in bacterial meningitis: an
interplay of bacterial and host driven toxicity. J Neuroimmunol 2007,
184:45-52.
9. van de Beek D, Farrar JJ, de Gans J, Mai NT, Molyneux EM, Peltola H,
Peto TE, Roine I, Scarborough M, Schultsz C, et al: Adjunctive
dexamethasone in bacterial meningitis: a meta-analysis of individual
patient data. Lancet Neurol 9:254-263.
10. Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M, Pfister HW: Matrix
metalloproteinases contribute to the blood-brain barrier disruption
during bacterial meningitis. Ann Neurol 1998, 44:592-600.
11. Kastenbauer S, Klein M, Koedel U, Pfister HW: Reactive nitrogen species
contribute to blood-labyrinth barrier disruption in suppurative
labyrinthitis complicating experimental pneumococcal meningitis in the
rat. Brain Res 2001, 904:208-217.
12. Winter AJ, Marwick S, Osborne M, Comis S, Stephen J, Tarlow M:
Ultrastructural damage to the organ of corti during acute experimental
Escherichia coli and pneumococcal meningitis in guinea pigs. Acta
Otolaryngol 1996, 116:401-407.
13. Caye-Thomasen P, Worsoe L, Brandt CT, Miyazaki H, Ostergaard C, Frimodt-
Moller N, Thomsen J: Routes, dynamics, and correlates of cochlear
inflammation in terminal and recovering experimental meningitis.
Laryngoscope 2009, 119:1560-1570.
14. Meli DN, Coimbra RS, Erhart DG, Loquet G, Bellac CL, Tauber MG,
Neumann U, Leib SL: Doxycycline reduces mortality and injury to the
brain and cochlea in experimental pneumococcal meningitis. Infect
Immun 2006, 74:3890-3896.
15. Tinling SP, Colton J, Brodie HA: Location and timing of initial osteoid
deposition in postmeningitic labyrinthitis ossificans determined by
multiple fluorescent labels. Laryngoscope 2004, 114:675-680.
16. Winter AJ, Comis SD, Osborne MP, Tarlow MJ, Stephen J, Andrew PW, Hill J,
Mitchell TJ: A role for pneumolysin but not neuraminidase in the hearing
loss and cochlear damage induced by experimental pneumococcal
meningitis in guinea pigs. Infect Immun 1997, 65:4411-4418.
17. Miller JM, Chi DH, O’Keeffe LJ, Kruszka P, Raphael Y, Altschuler RA:
Neurotrophins can enhance spiral ganglion cell survival after inner hair
cell loss. Int J Dev Neurosci 1997, 15:631-643.
18. Nadol JB Jr, Young YS, Glynn RJ: Survival of spiral ganglion cells in
profound sensorineural hearing loss: implications for cochlear
implantation. Ann Otol Rhinol Laryngol 1989, 98:411-416.
19. Lyxell B, Andersson J, Andersson U, Arlinger S, Bredberg G, Harder H:
Phonological representation and speech understanding with cochlear
implants in deafened adults. Scand J Psychol 1998, 39:175-179.
20. Pisoni DB, Geers AE: Working memory in deaf children with cochlear
implants: correlations between digit span and measures of spoken
language processing. Ann Otol Rhinol Laryngol Suppl 2000, 185:92-93.
21. Yukawa K, Cohen L, Blamey P, Pyman B, Tungvachirakul V, O’Leary S: Effects
of insertion depth of cochlear implant electrodes upon speech
perception. Audiol Neurootol 2004, 9:163-172.
22. Fayad JN, Linthicum FH Jr: Multichannel cochlear implants: relation of
histopathology to performance. Laryngoscope 2006, 116:1310-1320.
23. Nadol JB Jr, Hsu WC: Histopathologic correlation of spiral ganglion cell
count and new bone formation in the cochlea following meningogenic
labyrinthitis and deafness. Ann Otol Rhinol Laryngol 1991, 100:712-716.
24. Nadol JB Jr: Patterns of neural degeneration in the human cochlea and
auditory nerve: implications for cochlear implantation. Otolaryngol Head
Neck Surg 1997, 117:220-228.
25. Fritzsch B, Tessarollo L, Coppola E, Reichardt LF: Neurotrophins in the ear:
their roles in sensory neuron survival and fiber guidance. Prog Brain Res
2004, 146:265-278.
26. Lewin GR, Barde YA: Physiology of the neurotrophins. Annu Rev Neurosci
1996, 19:289-317.
27. Wise AK, Hume CR, Flynn BO, Jeelall YS, Suhr CL, Sgro BE, O’Leary SJ,
Shepherd RK, Richardson RT: Effects of Localized Neurotrophin Gene
Expression on Spiral Ganglion Neuron Resprouting in the Deafened
Cochlea. Mol Ther 2010, 18(6):1111-22.
28. Ernfors P, Van De Water T, Loring J, Jaenisch R: Complementary roles of
BDNF and NT-3 in vestibular and auditory development. Neuron 1995,
14:1153-1164.
29. Altschuler RA, Cho Y, Ylikoski J, Pirvola U, Magal E, Miller JM: Rescue and
regrowth of sensory nerves following deafferentation by neurotrophic
factors. Ann N Y Acad Sci 1999, 884:305-311.
30. Ernfors P, Duan ML, ElShamy WM, Canlon B: Protection of auditory
neurons from aminoglycoside toxicity by neurotrophin-3. Nat Med 1996,
2:463-467.
31. Staecker H, Kopke R, Malgrange B, Lefebvre P, Van de Water TR: NT-3 and/
or BDNF therapy prevents loss of auditory neurons following loss of hair
cells. Neuroreport 1996, 7:889-894.
32. Richardson RT, Wise AK, Thompson BC, Flynn BO, Atkinson PJ, Fretwell NJ,
Fallon JB, Wallace GG, Shepherd RK, Clark GM, O’Leary SJ: Polypyrrole-
coated electrodes for the delivery of charge and neurotrophins to
cochlear neurons. Biomaterials 2009, 30:2614-2624.
33. Shepherd RK, Coco A, Epp SB: Neurotrophins and electrical stimulation
for protection and repair of spiral ganglion neurons following
sensorineural hearing loss. Hear Res 2008, 242:100-109.
34. Chaudhuri A, Martinez-Martin P, Kennedy PG, Andrew Seaton R, Portegies P,
Bojar M, Steiner I: EFNS guideline on the management of community-
acquired bacterial meningitis: report of an EFNS Task Force on acute
bacterial meningitis in older children and adults. Eur J Neurol 2008,
15:649-659.
35. Kim HH, Addison J, Suh E, Trune DR, Richter CP: Otoprotective effects of
dexamethasone in the management of pneumococcal meningitis: an
animal study. Laryngoscope 2007, 117:1209-1215.
36. Klein M, Koedel U, Pfister HW, Kastenbauer S: Meningitis-associated
hearing loss: protection by adjunctive antioxidant therapy. Ann Neurol
2003, 54:451-458.
37. Noben-Trauth K, Zheng QY, Johnson KR: Association of cadherin 23 with
polygenic inheritance and genetic modification of sensorineural hearing
loss. Nat Genet 2003, 35:21-23.
38. Johnson KR, Zheng QY, Noben-Trauth K: Strain background effects and
genetic modifiers of hearing in mice. Brain Res 2006, 1091:79-88.
39. Koedel U, Bayerlein I, Paul R, Sporer B, Pfister HW: Pharmacologic
interference with NF-kappaB activation attenuates central nervous
system complications in experimental Pneumococcal meningitis. J Infect
Dis 2000, 182:1437-1445.
40. Kuo LT, Simpson A, Schanzer A, Tse J, An SF, Scaravilli F, Groves MJ: Effects
of systemically administered NT-3 on sensory neuron loss and nestin
expression following axotomy. J Comp Neurol 2005, 482:320-332.
41. Alcala-Barraza SR, Lee MS, Hanson LR, McDonald AA, Frey WH, McLoon LK:
Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4
to the CNS. J Drug Target 2010, 18:179-190.
42. Pettingill LN, Minter RL, Shepherd RK: Schwann cells genetically modified
to express neurotrophins promote spiral ganglion neuron survival in
vitro. Neuroscience 2008, 152:821-828.
43. Terayama Y, Kaneko K, Tanaka K, Kawamoto K: Ultrastructural changes of
the nerve elements following disruption of the organ of Corti. II. Nerve
elements outside the organ of Corti. Acta Otolaryngol 1979, 88:27-36.
44. McGuinness SL, Shepherd RK: Exogenous BDNF rescues rat spiral
ganglion neurons in vivo. Otol Neurotol 2005, 26:1064-1072.
45. Dicou E, Masson C, Jabbour W, Nerriere V: Increased frequency of NGF in
sera of rheumatoid arthritis and systemic lupus erythematosus patients.
Neuroreport 1993, 5:321-324.
46. Bonini S, Lambiase A, Angelucci F, Magrini L, Manni L, Aloe L: Circulating
nerve growth factor levels are increased in humans with allergic
diseases and asthma. Proc Natl Acad Sci USA 1996, 93:10955-10960.
Demel et al. Journal of Neuroinflammation 2011, 8:7
http://www.jneuroinflammation.com/content/8/1/7
Page 11 of 1247. Azar ST, Major SC, Safieh-Garabedian B: Altered plasma levels of nerve
growth factor and transforming growth factor-beta2 in type-1 diabetes
mellitus. Brain Behav Immun 1999, 13:361-366.
48. Quarcoo D, Fischer TC, Peckenschneider N, Groneberg DA, Welker P: High
abundances of neurotrophin 3 in atopic dermatitis mast cell. J Occup
Med Toxicol 2009, 4:8.
49. Gadient RA, Cron KC, Otten U: Interleukin-1 beta and tumor necrosis
factor-alpha synergistically stimulate nerve growth factor (NGF) release
from cultured rat astrocytes. Neurosci Lett 1990, 117:335-340.
50. Tsao D, Thomsen HK, Chou J, Stratton J, Hagen M, Loo C, Garcia C,
Sloane DL, Rosenthal A, Lin JC: TrkB agonists ameliorate obesity and
associated metabolic conditions in mice. Endocrinology 2008,
149:1038-1048.
51. Apfel SC: Neurotrophic factors in peripheral neuropathies: therapeutic
implications. Brain Pathol 1999, 9:393-413.
52. Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML,
Cedarbaum JM, Mendell JR: NT-3 promotes nerve regeneration and
sensory improvement in CMT1A mouse models and in patients.
Neurology 2005, 65:681-689.
53. Klein M, Paul R, Angele B, Popp B, Pfister HW, Koedel U: Protein expression
pattern in experimental pneumococcal meningitis. Microbes Infect 2006,
8:974-983.
54. Nau R, Gerber J, Bunkowski S, Bruck W: Axonal injury, a neglected cause
of CNS damage in bacterial meningitis. Neurology 2004, 62:509-511.
55. Kesser BW, Hashisaki GT, Spindel JH, Ruth RA, Scheld WM: Time course of
hearing loss in an animal model of pneumococcal meningitis.
Otolaryngol Head Neck Surg 1999, 120:628-637.
56. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM,
Whitley RJ: Practice guidelines for the management of bacterial
meningitis. Clin Infect Dis 2004, 39:1267-1284.
57. van de Beek D, Farrar JJ, de Gans J, Mai NT, Molyneux EM, Peltola H,
Peto TE, Roine I, Scarborough M, Schultsz C, et al: Adjunctive
dexamethasone in bacterial meningitis: a meta-analysis of individual
patient data. Lancet Neurol 2010, 9:254-263.
doi:10.1186/1742-2094-8-7
Cite this article as: Demel et al.: Reduced spiral ganglion neuronal loss
by adjunctive neurotrophin-3 in experimental pneumococcal
meningitis. Journal of Neuroinflammation 2011 8:7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Demel et al. Journal of Neuroinflammation 2011, 8:7
http://www.jneuroinflammation.com/content/8/1/7
Page 12 of 12